|
Name of OPV cessation timing option
|
Number of VAPP cases 2015-2019
|
Polio vaccine use 2015–2019 (billions of doses)a
|
|---|
|
PV1
|
PV2
|
PV3
|
Total
|
tOPV
|
bOPV
|
mOPV1
|
IPV
|
All polio vaccine
|
|---|
|
Current timing plan
|
41
|
75
|
404
|
520
|
3.3
|
8.2
|
0
|
1.3
|
12.8
|
|
OPV23 cessation in 2017
|
42
|
122
|
219
|
383
|
5.2
|
1.3
|
4.9
|
1.3
|
12.8
|
|
OPV123 cessation in 2018
|
34
|
168
|
302
|
504
|
7.1
|
1.9
|
0
|
1.4
|
10.4
|
|
OPV123 cessation in 2019
|
43
|
214
|
383
|
634
|
9.0
|
2.5
|
0
|
1.3
|
12.8
|
|
OPV123 cessation in 2019 with tOPV-only from 2017
|
44
|
210
|
382
|
635
|
10.1
|
1.3
|
0
|
1.3
|
12.8
|
|
OPV123 cessation in 2019 with IPV added from 2018
|
58
|
252
|
499
|
810
|
9.2
|
2.5
|
0
|
0.8
|
12.4
|
- Abbreviations: bOPV, bivalent OPV (serotypes 1 and 3); cVPDV, circulating vaccine-derived poliovirus; IPV, inactivated poliovirus vaccine; mOPV1, serotype 1 monovalent OPV; OPV, oral poliovirus vaccine; OPV(##) cessation, globally-coordinated cessation of OPV containing the serotype(s) indicated by ##; PV(1,2,3), poliovirus (serotype 1, 2, or 3, respectively); RI, routine immunization; SIA, supplemental immunization activity; tOPV, trivalent OPV; VAPP, vaccine-associated paralytic poliomyelitis
- aIncludes RI and planned, preventive SIAs, with no outbreak response SIAs triggered for any of the options
